Yee Chung Cheng, MD, discusses the importance of integrating neoadjuvant and adjuvant trial data into practice in order to optimize outcomes for patients with early-stage HER2-positive breast cancer.
Ross Mudgway, discusses the importance of considering surgery for patients with stage IV HER2-positive breast cancer and addresses disparities in healthcare among different social groups.
The European Medicines Agency has validated and accepted a marketing authorization application for the trastuzumab biosimilar HD201 (Tuznue), according to the developer Prestige BioPharma.
Joanne Mortimer, MD, discusses key facets of treatment for patients with early and metastatic HER2-positive breast cancer.
The antibody-drug conjugate [fam-] trastuzumab deruxtecan (DS-8201) demonstrated encouraging responses in patients with unresectable and/or metastatic HER2-positive breast cancer that has been previously treated with ado-trastuzumab emtansine, according to topline findings from the phase II DESTINY-BreastO1 study.
The FDA has approved ado-trastuzumab emtansine (T-DM1; Kadcyla) for use as an adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease following neoadjuvant trastuzumab and chemotherapy.
Sandoz has entered into an agreement with EirGenix, Inc., to commercialize the proposed trastuzumab biosimilar EG12014 for use as a treatment of patients with HER2-positive breast and select gastric cancers.
A new VENTANA HER2 dual in situ hybridization companion diagnostic assay has launched to identify HER2 amplification for patients with breast cancer and gastric cancer who could be eligible to receive trastuzumab.
Cindy Osborne, MD, highlights the many advances that have been made in the treatment paradigms of locally advanced and metastatic HER2-positive breast cancer.
Mark D. Pegram, MD, highlights data from pivotal studies that have helped to shape the current landscape of HER2-positive breast cancer and sheds light on emerging agents that are showing promise in the pipeline.